Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Aligos Therapeutics, Inc. ALGS
$3.07
▼ -22.28%
($-0.88)
🧊 52W Low
⬇️ Below Yest. Low
⚡ High Volume
🎈 Low Float
🎢 High Beta
Open
$4.00
Prev Close
$3.95
Day Range
$2.80 – $4.01
52W Range
$3.95 – $13.69
Market Cap
$24.67M
Beta
2.59
EPS (TTM)
$-7.31
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-16 |
| Shares Out. | 6,240,000 |
| Website | aligos.com ↗ |
| Phone | 13026587581 |
| Employees | 82 |
| Revenue | $27.8M |
| Gross Profit | $27.8M |
| Net Income | -$1.5M |
| Free Cash Flow | -$94.5M |
| Total Assets | $66.3M |
| Total Liabilities | $34.4M |
| Equity | $31.9M |
About Aligos Therapeutics, Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Aligos Therapeutics, Inc. is a publicly traded company under the ticker symbol ALGS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-11-01)